Inconsistent ALS Trial Analysis Increases Risk of False Positive Results

The Statistical Vulnerability of Functional Endpoints in Amyotrophic Lateral Sclerosis

Clinical management and regulatory approval in amyotrophic lateral sclerosis rely heavily on the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) to monitor disease progression [1]. This validated instrument serves as the primary endpoint for most pivotal trials, including recent investigations into sodium phenylbutyrate-taurursodiol and antisense oligonucleotides like tofersen [2, 3]. However, the field continues to struggle with identifying effective disease-modifying therapies, as evidenced by the failure of agents such as memantine, trazodone, and trehalose in large-scale adaptive platform trials [4, 5]. While the scale itself is standardized, a systematic review of 45 randomized trials involving 7,338 patients identified 39 distinct statistical methods used to interpret its changes, leading to treatment effect estimates that varied by as much as 3.66 standard deviations [6]. This analysis suggests that nearly 39 percent of current analytical strategies risk increasing false-positive rates, which is the probability of concluding a treatment is effective when it is actually inert, potentially skewing clinical perceptions of benefit and complicating drug development [6].

A Fragmented Landscape of Clinical Trial Methodology

To evaluate the consistency of data interpretation in amyotrophic lateral sclerosis research, investigators conducted a systematic search of the PubMed and Embase databases to identify randomized, placebo-controlled clinical trials that utilized the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) as their primary endpoint. The inclusion criteria required each trial to have at least 20 randomly assigned patients and a minimum follow-up period of 12 weeks to ensure the findings reflected sustained clinical observations. This search strategy yielded a substantial dataset for analysis, encompassing 45 randomized clinical trials with a combined sample size of 7,338 patients. The review focused on extracting specific data regarding the statistical analysis approaches and the strategies employed for handling missing data, which is a frequent complication in neurodegenerative disease trials due to high rates of patient attrition from disability or death.

The researchers identified 39 distinct statistical methods used across these trials to interpret the same functional scale. These approaches included a mixture of longitudinal techniques, which track patient data over multiple time points to observe the trajectory of functional decline, and cross-sectional techniques, which compare patient groups at a single snapshot in time. This lack of uniformity in how the ALSFRS-R is analyzed creates a fragmented landscape where the same clinical data could lead to different conclusions depending on the mathematical model applied. For the practicing physician, this means that two trials testing the same drug could report different results not because of biological differences in the patient populations, but because of the specific statistical framework chosen by the investigators.

Quantifying the Risk of Erroneous Treatment Efficacy

To determine how these 39 different statistical methods impact clinical conclusions, the researchers conducted a simulation study using the Ceftriaxone trial data set to model a realistic trial scenario. This approach allowed the authors to assess two critical metrics: validity and precision. In this clinical context, the researchers defined validity as the false-positive rate, which represents the risk of concluding a treatment is effective when it is actually inert. They defined precision as statistical power, which is the probability that a trial will correctly detect a true treatment effect of a given magnitude. By applying various mathematical models to this established patient data set, the study demonstrated how the choice of analysis alone can fundamentally alter the perceived efficacy of a therapeutic intervention.

The results of this simulation revealed that the choice of statistical method can lead to a dramatic range of outcomes even when the underlying patient data remain identical. Applying different methods to the same trial data set resulted in estimated treatment effect sizes ranging from a negative 1.33 to a positive 2.33 standard deviation difference. This variance suggests that a drug could appear either harmful or highly beneficial depending solely on the mathematical lens used by the investigators. Furthermore, the study found that 38.9 percent (95% CI 24.8 percent to 55.1 percent) of the identified methods were at risk of increasing false-positive rates. For the practicing physician, this means that nearly four out of ten statistical approaches used in these trials could lead to the erroneous advancement of ineffective treatments, potentially exposing patients to unnecessary side effects without clinical benefit. Beyond the risk of false positives, the researchers identified significant inconsistencies in the ability of these trials to detect real therapeutic benefits. Among the strategies deemed statistically valid, the statistical power varied widely, ranging from a low of 17.9 percent to a high of 78.2 percent. A power of 17.9 percent indicates a high likelihood of a type II error, where a truly effective medication is discarded because the trial was not mathematically sensitive enough to capture its impact.

The Impact of Underutilized Longitudinal Data

The systematic review of 45 randomized clinical trials revealed a significant oversight in how patient progress is tracked and analyzed during drug development. The researchers found that most trials (55.6 percent) failed to use all available longitudinal ALSFRS-R measurements, which are the repeated assessments of a patient's functional status collected at multiple time points throughout the study duration. By focusing on limited data points, such as the final assessment only, rather than the full sequence of measurements, investigators failed to capture the complete trajectory of disease progression or treatment response for the 7,338 patients included in the meta-analysis. This methodological choice has direct implications for the reliability of trial outcomes and the evidence base available to clinicians.

The failure to utilize all longitudinal data resulted in suboptimal utilization of patient data and reduced statistical precision, a term referring to the mathematical consistency and stability of the treatment effect estimate. For the practicing physician, this reduction in precision means that a trial is less likely to provide a clear, reliable answer about whether a medication actually slows functional decline. When statistical precision is compromised, the resulting data are more susceptible to random noise, making it difficult to distinguish a genuine therapeutic signal from chance. Ultimately, this practice fails to fully leverage the valuable contributions of patients who undergo frequent, intensive clinical assessments, as their repeated data points are not fully integrated into the final analysis of the drug's efficacy. This inefficiency can lead to inconclusive results in trials that might have otherwise shown a clear benefit if all collected data had been utilized.

Standardization as a Path to Clinical Certainty

The lack of a standardized analytical framework for the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) introduces significant noise into the clinical evidence base. Because the choice of statistical method can influence estimated treatment effects, clinicians are often presented with data that may not reflect the true biological impact of a therapy. In this study, applying different analytical techniques to the same patient data resulted in treatment effect estimates ranging from a negative 1.33 to a positive 2.33 standard deviation difference. This wide variance suggests that a drug might appear beneficial or harmful simply based on the mathematical model selected, potentially resulting in misleading conclusions and uncertainty about drug efficacy. For the neurologist at the bedside, this means that the reported benefit of a new intervention may be an artifact of the analysis rather than a reproducible clinical improvement.

Beyond the individual trial, this methodological variability limits the interpretability and comparability of clinical trials, creating a fragmented landscape where one study cannot be easily weighed against another. This lack of consistency influences clinical decision-making and drug development by obscuring which compounds truly merit advancement into late-stage trials or clinical practice. When 38.9 percent (95 percent CI 24.8 percent to 55.1 percent) of methods carry an increased risk of false positives, the pipeline for neurodegenerative therapies becomes cluttered with ineffective treatments that may have been advanced erroneously. This systemic uncertainty forces physicians to make prescribing choices based on unstable data, which can delay the adoption of truly effective interventions while exposing patients to the risks and costs of medications that lack a robust evidence base. To address these inconsistencies, the researchers suggest that establishing statistical consensus recommendations could improve the utility of disability scales like the ALSFRS-R. By standardizing how functional data are handled, the medical community can ensure that trial results are both precise and comparable across different therapeutic candidates, providing a more reliable foundation for evidence-based medicine.

References

1. Leigh PN, Swash M, Iwasaki Y, et al. Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial.. Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. 2004. doi:10.1080/14660820410020187

2. Hamad AA, Alkhawaldeh IM, Nashwan A, Meshref M, Imam Y. Tofersen for SOD1 amyotrophic lateral sclerosis: a systematic review and meta-analysis. Neurological Sciences. 2025. doi:10.1007/s10072-025-07994-2

3. Paganoni S, Macklin EA, Hendrix S, et al. Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis. New England Journal of Medicine. 2020. doi:10.1056/nejmoa1916945

4. Pal S, Chataway J, Swingler R, et al. Safety and efficacy of memantine and trazodone versus placebo for motor neuron disease (MND SMART): stage two interim analysis from the first cycle of a phase 3, multiarm, multistage, randomised, adaptive platform trial.. Lancet Neurology. 2024. doi:10.1016/s1474-4422(24)00326-0

5. Safety and efficacy of trehalose in amyotrophic lateral sclerosis (HEALEY ALS Platform Trial): an adaptive, phase 2/3, double-blind, randomised, placebo-controlled trial.. Lancet Neurology. 2025. doi:10.1016/s1474-4422(25)00173-5

6. Weemering DN, Unnik JWJV, Genge A, Berg LHVD, Eijk RPAV. Heterogeneity in the Analysis of the ALSFRS-R in ALS Clinical Trials and its Effect on the Validity and Precision of Trial Conclusions.. Neurology. 2026. doi:10.1212/WNL.0000000000214937